Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Vismodegib
Drug ID BADD_D02365
Description Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Indications and Usage Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Marketing Status approved; investigational
ATC Code L01XJ01
DrugBank ID DB08828
KEGG ID D09992
MeSH ID C538724
PubChem ID 24776445
TTD Drug ID D03EDQ
NDC Product Code 50242-140
UNII 25X868M3DS
Synonyms HhAntag691 | NSC 747691 | NSC747691 | NSC-747691 | R 3616 | R3616 cpd | R-3616 | vismodegib | erivedge | GDC 0449 | GDC0449 | GDC-0449 | RG 3616 | RG3616 | RG-3616
Chemical Information
Molecular Formula C19H14Cl2N2O3S
CAS Registry Number 879085-55-9
SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
General physical health deterioration08.01.03.0180.000918%Not Available
Muscle fatigue15.05.03.0060.000302%Not Available
Tumour haemorrhage16.32.03.008; 24.07.01.0280.000112%
Lung cancer metastatic16.19.02.003; 22.08.01.0040.000246%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000437%
Madarosis23.02.02.004; 06.06.04.0100.001936%Not Available
Ingrown hair23.02.06.0080.000246%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000492%Not Available
Fluid intake reduced14.05.10.0010.000381%Not Available
Pulmonary mass22.02.07.0040.000168%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000246%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000739%
Precocious puberty21.03.02.009; 05.05.03.0010.000112%
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000280%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.001019%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Appetite disorder19.09.01.002; 14.03.01.0040.000246%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000112%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.0030.000772%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000873%Not Available
Embolism24.01.01.0090.000560%
Malnutrition14.03.02.0040.000168%Not Available
Metastatic neoplasm16.16.01.0070.000414%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.015480%
Erectile dysfunction21.03.01.007; 19.08.04.0010.000683%
Ill-defined disorder08.01.03.0490.001668%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages